Fibrostenotic Inflammatory Bowel Disease

Examines both pathophysiological and clinical aspects of the disease
Offers access to videos for medical and surgical intervention
Discusses current and future drug therapies

Examines both pathophysiological and clinical aspects of the disease Offers access to videos for medical and surgical intervention Discusses current and future drug therapies

Autorentext

Dr. Rieder is a principal investigator at the Department of Inflammation and Immunity and an Associate Clinical Staff at the Department of Gastroenterology, Hepatology & Nutrition at the Cleveland Clinic, Cleveland. His focus is the field of pathogenesis, prediction and therapy of intestinal fibrosis. He is a fully trained Internist and Gastroenterologist with an IBD focussed clinical and endoscopic practice. He initiated and organized international clinical consensus meetings. Dr. Rieder published more than 70 articles and book chapters in high impact journals, including Science Translational Medicine, Gastroenterology and Gut. He has been recognized for his expertise as indicated through invitations to the steering committee of the 2nd European Crohn's and Colitis Organization (ECCO) scientific workshop on 'Intestinal healing', group leader of the 4th ECCO scientific workshop on 'Intestinal fibrosis', invitations as a full member of the consensus panel of the ECCO guidelines on Crohn's disease, lead author of the ECCO guidelines on Ulcerative colitis and lead author of the first ECCO clinical consensus on 'Diagnosis and Management of Intestinal Fibrosis' as well as multiple international invitations as a speaker, session chair or conference faculty. Dr. Rieder is an associate editor (Clinical and Translational Gastroenterology) and on several editorial boards of medical journals (Journal of Crohn's and Colitis, Inflammatory Bowel Disease, Gastroenterology and Hepatology, Fibrogenesis and Tissue Repair, American Journal of Physiology Gastrointestinal and Liver Physiology). He is proud of his significant ties to the ECCO, which he served as the chair of Y-ECCO, member of the ECCO operational board and currently member of the scientific committee. He is REACH-IBD and is a member of the Professional Education Committee of the CCFA.

Inhalt

Fibrostenotic Inflammatory Bowel Disease a Cinderella story.- Epidemiology and Natural History of Fibrostenosing Inflammatory Bowel Disease.- Genetic influences on the development of fibrosis in inflammatory bowel disease.- Epigenetic regulation of intestinal fibrosis.- Cytokine and Anti-cytokine Agents as Future Therapeutics for Fibrostenosing IBD.- Inflammation-independent mechanisms of intestinal fibrosis: the role of the extracellular matrix.- Fat and Fibrosis.- Environmental factors and their influence on intestinal fibrosis.- Animal models and sources of mesenchymal cells in intestinal fibrosis.- Fibrosis in Ulcerative Colitis.- Histopathology of intestinal fibrosis.- Clinical, Cellular and Serologic Biomarkers of intestinal fibrosis.- The future of intestinal fibrosis imaging.- Imaging in intestinal fibrosis. What is state of the art?.- Medical therapy of stricturing IBD.- Endoscopic therapy of intestinal strictures What is state of the art?.- Resectional surgery for intestinal strictures What is state of the art?.- Management of ileal pouch strictures and anal stricturing disease A clinical challenge.- The future of surgical therapy of stricturing IBD.- Challenges of translation of anti-fibrotic therapies into clinical practice in IBD.- What distinguishes mechanisms of fistula and stricture formation.- The Pathogenesis of Intraabdominal Adhesions:Similarities and Differences to Luminal Fibrosis.- Anti-fibrotic therapies from other organs What the gut can learn from the liver, skin, lung and heart.

<p